4-(4-Aminophenoxy)-N-Methylpicolinamide CAS 284462-37-9 Sorafenib Tosylate Entèmedyè Faktori Segondè Pite
Pwovizyon Komèsyal Sorafenib Tosylate ak entèmedyè ki gen rapò:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
Non Chimik | 4-(4-Aminophenoxy)-N-Methylpicolinamide |
Sinonim | 4-(4-Aminophenoxy)-N-Methyl-2-Pyridinecarboxamide |
Nimewo CAS | 284462-37-9 |
Nimewo CAT | RF-PI166 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C13H13N3O2 |
Pwa molekilè | 243.27 |
Pwen k ap fonn | 110.0 ~ 112.0 ℃ |
Dansite | 1.241 g/cm3 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Limyè mawon poud blan poud |
Pite / Metòd analiz | 98.0% ~ 101.0% (sou baz cheche) (HPLC) |
Pèt sou siye | ≤0.50% |
Rezid sou ignisyon | ≤0.20% |
Single enpurte | ≤0.20% |
Total enpurte | ≤1.0% |
Metal lou | ≤20ppm |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè Sorafenib Tosylate (CAS: 475207-59-1) |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
![1](https://www.ruifuchemical.com/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
Manifakti ak pite segondè ak bon jan kalite ki estab
Pwovizyon komèsyal Sorafenib Tosylate (CAS: 475207-59-1) Entèmedyè ki gen rapò:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
Sorafenib Tosylate (CAS: 475207-59-1) se yon nouvo kalite dwòg anti-tumeur milti-sib, te devlope pa Alman Bayer Pharmaceuticals yo, epi li montre aktivite anti-tumeur awogan nan tès preklinik sou bèt.Sorafenib disponib nan tablèt 200 mg pou administrasyon oral epi li itilize nan tretman RCC ak HCC.